India Cracks Down on Unregulated Use of Cheap Generic Weight-Loss Drugs Amid Health Risk Warnings

Kathmandu. India has issued a stern warning regarding the misuse and health risks associated with the rapid proliferation of cheap generic versions of weight-loss drugs in the market. The Ministry of Health stated that it has tightened monitoring and enforcement due to the potential increase in irregularities in drug usage.

Generic production of semaglutide, the active ingredient in drugs like Ozempic and Wegovy, has rapidly entered the Indian market following the expiration of its patent on March 20. India, considered the world's largest supplier of generic medicines, has increased access by lowering prices.

These GLP-1 class drugs are considered effective against obesity because they influence blood glucose levels and hunger-regulating hormones. However, the Ministry of Health has warned that serious side effects can occur if these drugs are used without a doctor's prescription.

According to the Ministry, with various generic variants now available in the market, the risk of uncontrolled sales through retail pharmacies, online platforms, wholesalers, and wellness clinics has increased. "Use without proper medical supervision can lead to serious health problems," the Ministry clarified.

In response, India's drug regulatory body has stated it is tightening inspections and has banned manufacturers from engaging in activities that promote misleading advertising or the improper use of the drugs.

Simon Barkera, President of the World Obesity Federation, stated that drugs alone cannot solve the problem of obesity. According to him, as obesity is a complex and chronic disease, a healthy lifestyle and preventive measures are equally essential.

The market for weight-loss drugs in India has grown rapidly over the last five years. Its turnover reached $153 million by 2026 and is projected to exceed half a billion dollars by 2030.

According to the World Health Organization, although one-third of the world's malnutrition burden still lies in India, the rate of obesity is rapidly increasing due to rising income and urban lifestyles. Government statistics show that 24% of women and 23% of men in India are overweight or obese.

Previously, the monthly cost of such drugs ranged from 15,000 to 22,000 Indian Rupees, limiting their use. However, after the patent expired, the price of generic semaglutide has dropped to between 1,300 and 4,200 Rupees, expanding its scope of use.

Nevertheless, with cheaper prices comes an increased risk of uncontrolled use, highlighting the need for India to exercise special caution regarding the safe use of these medications.